CL2020000166A1 - Compuestos bifuncionales. - Google Patents
Compuestos bifuncionales.Info
- Publication number
- CL2020000166A1 CL2020000166A1 CL2020000166A CL2020000166A CL2020000166A1 CL 2020000166 A1 CL2020000166 A1 CL 2020000166A1 CL 2020000166 A CL2020000166 A CL 2020000166A CL 2020000166 A CL2020000166 A CL 2020000166A CL 2020000166 A1 CL2020000166 A1 CL 2020000166A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- bifunctional compounds
- bifunctional
- compounds
- glp
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 230000001588 bifunctional effect Effects 0.000 title abstract 2
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 abstract 1
- 229940122392 PCSK9 inhibitor Drugs 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 abstract 1
- 230000004580 weight loss Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
Abstract
LA SOLICITUD DESCRIBE COMPUESTOS ÚTILES EN EL TRATAMIENTO DE LA DIABETES, PÉRDIDA DE PESO Y/O REDUCCIÓN DE RIESGOS CARDIOVASCULARES. LOS COMPUESTOS SON BIFUNCIONALES Y, POR LO TANTO, ADECUADOS COMO UN TRATAMIENTO SIMPLE PARA PACIENTES QUE PUEDEN BENEFICIARSE DEL TRATAMIENTO CON UN AGONISTA DEL RECEPTOR DE GLP-1 Y UN INHIBIDOR DE PCSK9.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17182010 | 2017-07-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020000166A1 true CL2020000166A1 (es) | 2020-06-12 |
Family
ID=59383423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020000166A CL2020000166A1 (es) | 2017-07-19 | 2020-01-17 | Compuestos bifuncionales. |
Country Status (16)
Country | Link |
---|---|
US (1) | US11130794B2 (es) |
EP (1) | EP3655427A1 (es) |
JP (1) | JP7339236B2 (es) |
KR (1) | KR20200037793A (es) |
CN (1) | CN110945017A (es) |
AR (1) | AR112760A1 (es) |
AU (1) | AU2018303625A1 (es) |
BR (1) | BR112020001286A2 (es) |
CA (1) | CA3068956A1 (es) |
CL (1) | CL2020000166A1 (es) |
CO (1) | CO2020001012A2 (es) |
IL (1) | IL272006A (es) |
MA (1) | MA49621A (es) |
PE (1) | PE20200720A1 (es) |
TW (1) | TW201918494A (es) |
WO (1) | WO2019016306A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HRP20220720T1 (hr) | 2016-01-13 | 2022-09-30 | Novo Nordisk A/S | Analozi egf(a) s masnim kiselinama kao supstituentima |
CN110357969B (zh) * | 2019-05-27 | 2022-03-08 | 北京志道生物科技有限公司 | 一种GLP1-EGFa异源二聚体蛋白、功能及方法 |
EP4085077A4 (en) | 2019-12-31 | 2024-01-17 | Beijing Ql Biopharmaceutical Co Ltd | FUSION PROTEINS FROM GLP-1 AND GDF15 AND CONJUGATES THEREOF |
CN115925994B (zh) | 2020-09-30 | 2023-09-22 | 北京质肽生物医药科技有限公司 | 多肽缀合物和使用方法 |
CN113429471B (zh) * | 2021-07-19 | 2022-12-23 | 青岛博睿精创科技有限公司 | 长效glp-1多肽类似物及其制备方法和应用 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1846446B1 (en) | 2005-02-02 | 2013-06-26 | Novo Nordisk A/S | Insulin derivatives |
WO2007022123A2 (en) | 2005-08-11 | 2007-02-22 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
TWI372629B (en) * | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
CA2616551A1 (en) | 2005-07-29 | 2007-02-15 | Amprotein Corporation | Chimeric therapeutic agents |
WO2007068718A1 (en) * | 2005-12-14 | 2007-06-21 | Novo Nordisk A/S | Polypeptide protracting tags |
JP2010535032A (ja) * | 2007-07-31 | 2010-11-18 | メディミューン,エルエルシー | 多重特異性エピトープ結合性タンパク質およびその用途 |
JP5721432B2 (ja) | 2007-08-15 | 2015-05-20 | ノボ・ノルデイスク・エー/エス | アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン |
CN101842109B (zh) * | 2007-09-05 | 2014-01-29 | 诺沃-诺迪斯克有限公司 | 用a-b-c-d-衍生的肽和它们的治疗用途 |
US20100317057A1 (en) * | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
JP5806110B2 (ja) | 2008-04-23 | 2015-11-10 | アムジエン・インコーポレーテツド | 中和プロタンパク質コンベルターゼズブチリシンケクシン9型(pcsk9)変形物及びその使用 |
WO2009143633A1 (en) | 2008-05-30 | 2009-12-03 | Institut De Recherches Cliniques De Montreal | Pcsk9 inhibitors and methods of use thereof |
TWI516501B (zh) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Pcsk9拮抗劑類 |
US8637647B2 (en) | 2008-09-12 | 2014-01-28 | Novo Nordisk A/S | Method of acylating a peptide or protein |
CN102333788A (zh) | 2009-02-19 | 2012-01-25 | 诺沃—诺迪斯克有限公司 | 因子viii的修饰 |
CN101993485B (zh) | 2009-08-20 | 2013-04-17 | 重庆富进生物医药有限公司 | 促胰岛素分泌肽类似物同源二聚体及其用途 |
CN102153652A (zh) | 2010-12-10 | 2011-08-17 | 浙江大学 | 一种融合蛋白的表达方法及用途 |
JP2014510516A (ja) | 2011-02-15 | 2014-05-01 | ノヴォ ノルディスク アー/エス | 長時間作用性il−1受容体アンタゴニスト |
BR112013032667A2 (pt) | 2011-06-20 | 2017-12-12 | Genentech Inc | polipeptídeo de ligação a pcsk9, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o polipeptídeo, composição farmacêutica, método de redução do nível de colesterol ldl em um sujeito, método de tratamento de disfunção relacionada ao colesterol em um sujeito, método de tratamento de hipercolesterolemia em um sujeito, método de inibição da ligação de pcsk9 a ldlr e método de detecção da proteína pcsk9 em uma amostra |
MX354705B (es) | 2011-09-23 | 2018-03-16 | Novo Nordisk As | Analogos de glucagon novedosos. |
TW201315742A (zh) | 2011-09-26 | 2013-04-16 | Novartis Ag | 治療代謝病症之雙功能蛋白質 |
US20140357838A1 (en) | 2011-12-21 | 2014-12-04 | Novo Nordisk A/S | N-Terminally Modified Insulin Derivatives |
WO2013098191A1 (en) | 2011-12-29 | 2013-07-04 | Novo Nordisk A/S | Dipeptide comprising a non-proteogenic amino acid |
CN112142855A (zh) | 2012-05-18 | 2020-12-29 | 爱德迪安(北京)生物技术有限公司 | 用于糖尿病治疗的蛋白、蛋白缀合物及其应用 |
AR092076A1 (es) | 2012-08-22 | 2015-03-18 | Lilly Co Eli | Proteinas homodimericas |
BR112015004734A2 (pt) | 2012-09-07 | 2017-11-21 | Sanofi Sa | proteínas de fusão para tratar uma síndrome metabólica |
MA38276B1 (fr) * | 2012-12-21 | 2018-03-30 | Sanofi Sa | Dérivés de l'exendine 4 pour l’utilisation dans le traitement des troubles du syndrome metabolique, y compris le diabete et l'obesite, ainsi que la reduction de l'apport alimentaire excessif. |
MY174727A (en) | 2013-04-18 | 2020-05-11 | Novo Nordisk As | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
BR112015032875A2 (pt) | 2013-07-04 | 2017-11-07 | Novo Nordisk As | derivados de peptídeos do tipo glp-1, e usos dos mesmos |
WO2015051214A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
CN106232627A (zh) * | 2014-02-21 | 2016-12-14 | 免疫医疗有限责任公司 | 抗pcsk9~glp‑1融合体及其使用方法 |
US10570184B2 (en) | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
CN104558198A (zh) | 2014-07-25 | 2015-04-29 | 成都贝爱特生物科技有限公司 | GLP-1类似物和amylin类似物的融合蛋白制备及其用途 |
WO2016147162A1 (en) | 2015-03-19 | 2016-09-22 | Institut De Cardiologie De Montreal | Grp94 derived polypeptides for inhibiting pcsk9 and methods of use |
CN105367884A (zh) | 2015-11-02 | 2016-03-02 | 陈薇 | 一种绝缘耐火抗辐射的屏蔽电缆材料及其制备方法 |
HRP20220720T1 (hr) | 2016-01-13 | 2022-09-30 | Novo Nordisk A/S | Analozi egf(a) s masnim kiselinama kao supstituentima |
JP2020527159A (ja) | 2017-07-19 | 2020-09-03 | ノヴォ ノルディスク アー/エス | Egf(a)類似体、その製造、製剤および使用 |
-
2018
- 2018-07-19 BR BR112020001286-6A patent/BR112020001286A2/pt not_active IP Right Cessation
- 2018-07-19 MA MA049621A patent/MA49621A/fr unknown
- 2018-07-19 PE PE2020000085A patent/PE20200720A1/es unknown
- 2018-07-19 KR KR1020207003735A patent/KR20200037793A/ko not_active Application Discontinuation
- 2018-07-19 JP JP2020500190A patent/JP7339236B2/ja active Active
- 2018-07-19 CA CA3068956A patent/CA3068956A1/en not_active Withdrawn
- 2018-07-19 AR ARP180102028A patent/AR112760A1/es unknown
- 2018-07-19 WO PCT/EP2018/069610 patent/WO2019016306A1/en unknown
- 2018-07-19 AU AU2018303625A patent/AU2018303625A1/en not_active Abandoned
- 2018-07-19 CN CN201880048047.1A patent/CN110945017A/zh active Pending
- 2018-07-19 EP EP18740854.7A patent/EP3655427A1/en active Pending
- 2018-07-19 TW TW107124975A patent/TW201918494A/zh unknown
- 2018-07-19 US US16/632,007 patent/US11130794B2/en active Active
-
2020
- 2020-01-13 IL IL272006A patent/IL272006A/en unknown
- 2020-01-17 CL CL2020000166A patent/CL2020000166A1/es unknown
- 2020-01-28 CO CONC2020/0001012A patent/CO2020001012A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP7339236B2 (ja) | 2023-09-05 |
MA49621A (fr) | 2020-05-27 |
CO2020001012A2 (es) | 2020-02-18 |
AR112760A1 (es) | 2019-12-11 |
IL272006A (en) | 2020-02-27 |
KR20200037793A (ko) | 2020-04-09 |
EP3655427A1 (en) | 2020-05-27 |
US20200231645A1 (en) | 2020-07-23 |
PE20200720A1 (es) | 2020-07-21 |
CN110945017A (zh) | 2020-03-31 |
CA3068956A1 (en) | 2019-01-24 |
TW201918494A (zh) | 2019-05-16 |
US11130794B2 (en) | 2021-09-28 |
WO2019016306A1 (en) | 2019-01-24 |
BR112020001286A2 (pt) | 2020-07-28 |
AU2018303625A1 (en) | 2020-02-06 |
JP2020528049A (ja) | 2020-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020000166A1 (es) | Compuestos bifuncionales. | |
AR102712A1 (es) | Agonistas parciales del receptor de insulina | |
CO2017001994A2 (es) | Compuestos activos hacia bromodominios | |
MX2020004467A (es) | Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r. | |
CL2019001465A1 (es) | Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip. | |
CL2016001911A1 (es) | Compuesto heterocíclico fusionado | |
DOP2017000097A (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
CR20150664A (es) | Moduladores de los receptores de estrógeno y sus usos | |
CL2018000596A1 (es) | Nuevos compuestos bicíclicos como inhibidores de la atx | |
CL2012003053A1 (es) | Combinacion farmaceutica que comprende un agonista del receptor glp-1 y linagliptin, inhibidor dpp-4; uso de la combinacion farmaceutica para el tratamiento de la diabetes tipo 2 y de la obesidad. | |
CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
CL2014001793A1 (es) | Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer. | |
CL2011000454A1 (es) | Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer. | |
UY34593A (es) | Miméticos sintéticos de apelina para el tratamiento de falla cardiaca | |
CR20170076A (es) | Derivados de pirimidima sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias | |
CL2016000009A1 (es) | Tratamiento de rosacea papulopustular con ivermectina. | |
PE20151871A1 (es) | Anticuerpos de receptor anti-glucagon y metodos de uso de los mismos | |
CL2015000976A1 (es) | Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados. | |
DOP2017000219A (es) | Formulacion de combinacion de tesofensina y betabloqueante | |
PH12018502274A1 (en) | Semaglutide in cardiovascular conditions | |
CL2015001574A1 (es) | Terapia combinada para el cancer | |
CU20170134A7 (es) | 2-tiopirimidinonas | |
CR20110012A (es) | Compuestos de fenantrenona, composiciones y métodos | |
BR112016028614A8 (pt) | novos agonistas de ep4, composição farmacêutica compreendendo os mesmos e seu uso | |
CL2016002653A1 (es) | Combinación farmacéutica que comprende brexpiprazol y nalmefeno; composición farmacéutica que los comprende; kit farmacéutico; y uso de la combinación para la prevención y tratamiento de un trastorno relacionado con sustancias como el alcohol. |